ArticleActas espanolas de psiquiatria2025
Ginsenoside Rg1 Promotes the Survival, Proliferation, and Differentiation of Senescent Neural Stem Cells Induced by D-galactose.
Article in Actas espanolas de psiquiatria, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploratory Effects of a Novel Nutraceutical on Senescence-Related Protein Biomarkers in Healthy Adults: A Pilot Proteomics Study.International journal of molecular sciences · 2026Trial
- Ginsenoside Rg1 delays the senescence of adipose-derived stem cells: network pharmacology and experimental validation.Hereditas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeural stem cells (NSCs) disrupt with aging, contributing to neurodegeneration. Ginsenoside Rg1 (Rg1), a compound found in Ginseng, is known for its anti-aging effects; however, its role in the progression of aging NSCs remains unclear. Therefore, this investigation explored the impact of Rg1 on the growth and maturation of aging NSC and elucidated its underlying molecular mechanisms.
methodsInitially, mouse models of brain aging were successfully established using D-galactose (D-gal) injection. Mice received Rg1 treatment along with D-gal administration. Brain tissues and NSCs were isolated and analyzed for pathological changes, gene expression, and cellular function. In vitro, experiments used aging NSCs treated with Rg1 to assess cell viability, proliferation, differentiation, and senescence markers.
resultsD-gal triggered aging-related pathological alterations in mouse brains, elevated acetylcholinesterase levels, upregulated senescence genes, and inhibited NSC proliferation (p < 0.05). However, Rg1 treatment mitigated D-gal-induced effects, delayed brain aging, and improved NSC function. In vitro, Rg1 significantly increased cell viability, promoted NSC proliferation and differentiation, reduced senescent neurons, and downregulated p53 and p21 genes (p < 0.05).
conclusionsRg1 demonstrates anti-aging properties in D-gal-induced mouse brain aging, promoting the proliferation and differentiation of NSCs, and downregulating the p53-p21 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.